Company intelligence / Profile preview
Ayk Biotechnology
Shanghai, Shanghai, China
- Ownership
- Private
- Development stage
- Other
01
Overview
Ayk Biotechnology has developed multiple next-generation adjuvants, a recombinant RSV vaccine (CHO cells) which received IND acceptance from the Chinese CDE in 2023, and a portfolio of tumor vaccines in preclinical/IND stage. Their adjuvant platform supports large-scale vaccine manufacturing, exceeding one million doses per batch, and encompasses over twenty proprietary immune-adjuvant molecules across six major classes[5][6].
- Therapeutic areas
- OncologyInfectious Diseases
- Modalities
- VaccineRecombinant proteinmRNA-based drugsAdjuvant
- Industry
- Biotech
02
Drug pipeline
3 assets2 more assets in the full pipeline.
Request access →Beyond the preview
Go deeper on Ayk Biotechnology.
Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.
Clinical trials
Full profile accessFollow clinical development from trial design and recruitment through results.
- Trial phase
- Status
- Readouts
Licensing & deals
Full profile accessExplore licensing agreements, acquisitions, and the assets behind each deal.
- Partners
- Deal terms
- Milestones
Funding history
Full profile accessTrace financing activity and the investors behind a company’s development.
- Funding rounds
- Investors
- Capital raised
Competitive landscape
Full profile accessCompare peer pipelines by target, modality, and therapeutic area.
- Peer companies
- Targets
- Pipeline overlap
Technologies & patents
Full profile accessExplore technology platforms and the patent landscape around relevant assets.
- Platforms
- Patents
- Assignees
Research & analysis
Full profile accessConnect company news and source material to the questions you’re investigating.
- Company news
- Sources
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on Ayk Biotechnology.